Professor Dr. Karl Hofbauer
Professor Hofbauer has extensive experience in the areas of metabolic disorders and cardiovascular disease. As a previous industry executive, he has an impressive track record in directing large global R&D efforts. He was appointed Professor for Applied Pharmacology at the University of Basel, where he is pursuing his research interests in the prevention and treatment of cardiovascular and metabolic risk factors.
A physician by training, Professor Hofbauer specialized in experimental pharmacology early in his career.
Subsequently he held several research management positions in the pharmaceutical industry. From 1996-2000 he was Therapeutic Area Head for Metabolic and Cardiovascular Diseases at Novartis, where he headed a global drug discovery team of over 200 scientists. Prior to this he was Head of Cardiovascular Biology at Ciba.
He and his team contributed successfully to the development of several major drugs, including Novartis' blockbuster antihypertensive agent (Diovan®).
He assists in the evaluation of investment opportunities.